| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBS |
| Uniprot No | Q9NRD0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-319aa |
| 氨基酸序列 | MGQGLWRVVR NQQLQQEGYS EQGYLTREQS RRMAASNISN TNHRKQVQGG IDIYHLLKAR KSKEQEGFIN LEMLPPELSF TILSYLNATD LCLASCVWQD LANDELLWQG LCKSTWGHCS IYNKNPPLGF SFRKLYMQLD EGSLTFNANP DEGVNYFMSK GILDDSPKEI AKFIFCTRTL NWKKLRIYLD ERRDVLDDLV TLHNFRNQFL PNALREFFRH IHAPEERGEY LETLITKFSH RFCACNPDLM RELGLSPDAV YVLCYSLILL SIDLTSPHVK NKMSKREFIR NTRRAAQNIS EDFVGHLYDN IYLIGHVAA |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与FBS重组蛋白相关的3篇参考文献，涵盖其应用及替代策略：
1. **文献名称**：*Recombinant Albumin as a Substitute for Fetal Bovine Serum in Cell Culture Media*
**作者**：Chen et al.
**摘要**：研究评估重组人白蛋白替代FBS在哺乳动物细胞培养中的效果，证明其能维持细胞增殖并减少批次差异，适用于生物制药生产。
2. **文献名称**：*Development of Serum-Free Media Using Recombinant Growth Factors for Stem Cell Expansion*
**作者**：Kim & Park
**摘要**：开发了一种无FBS培养基，通过添加重组FGF-2和EGF支持间充质干细胞生长，性能媲美含FBS培养基，减少动物源性成分依赖。
3. **文献名称**：*Recombinant Transferrin as an Alternative to FBS-Derived Proteins in Hybridoma Cultures*
**作者**：Rodriguez et al.
**摘要**：验证重组转铁蛋白替代FBS中天然转铁蛋白的可行性，显示其在杂交瘤细胞培养中维持抗体产量，提高培养基成分可控性。
(注：以上文献信息为示例性概括，具体文献需通过PubMed或Google Scholar检索确认。)
Fetal Bovine Serum (FBS) has been a cornerstone of cell culture for decades, providing essential nutrients, growth factors, and hormones for in vitro cell growth. However, its use raises ethical, scientific, and practical concerns, including batch-to-batch variability, ethical issues related to animal sourcing, and risks of viral or prion contamination. These limitations have driven demand for recombinant protein-based alternatives to FBS.
Recombinant proteins engineered through genetic modification offer a defined, animal-free solution. Produced in controlled systems (e.g., bacteria, yeast, or mammalian cells), these proteins replicate specific FBS components like growth factors (e.g., FGF, EGF), attachment factors (e.g., fibronectin), and carrier proteins (e.g., albumin). Their production ensures consistency, scalability, and reduced immunogenicity compared to serum-derived counterparts. This precision supports applications requiring regulatory compliance, such as therapeutic protein manufacturing and cell therapies.
The shift toward recombinant alternatives aligns with advancements in synthetic biology and bioprocessing. Customizable protein cocktails enable tailored microenvironments for specific cell types, particularly valuable for sensitive applications like stem cell expansion or vaccine production. While challenges remain in cost optimization and replicating serum's complex interactivity, recombinant systems increasingly support serum-free and chemically defined media formulations. Ongoing research focuses on expanding protein libraries and improving cost-efficiency through novel expression platforms, accelerating the transition from traditional serum-dependent cultures to more sustainable, ethical, and controlled bioprocessing workflows.
×
